A Panel of Experts Talk MDM in Healthcare: Three Takeaways

Posted by Ankit Jain on Mon, Jun 10, 2019

The potential of digital transformation is being realized across industries. In healthcare, advanced analytics has streamlined processes, sped up research and promises to drive better health outcomes. But advanced analytics are nothing without data, and unless you can break down data siloes across the enterprise and merge critical data into a single source of truth (otherwise known as master data management, or MDM), then your data will be insufficient to drive this kind of transformation.

I recently participated in a panel discussion for Informatica World 2019 with representatives from Intermountain Health and The American Cancer Society. We discussed MDM’s role in healthcare as a driver of digital transformation.

After reflecting on the conversation, I took three things away from the event:


>
Read More

Predictions for the Next Era of Vaccines

Posted by Jennifer Wong on Thu, May 30, 2019


Emmanuel Colliot, Joshua Hattem, Adi Natu, Bora Erdemli and Sarah Grace Tucker co-wrote this blog post with Jennifer Wong.

From April 15-17, ZS attended the World Vaccine Congress in Washington, D.C. for the first time, where more than 1,500 leading vaccines professionals from the pharma industry, academia, government and NGOs gathered to discuss the global future of vaccines. Topics ranged from critical success factors of creating effective private-public partnerships, to deep dives on the clinical challenges behind developing a universal flu vaccine, to the innovation of using microgravity in space to support vaccine development.


>
Read More

Veeva Summit 2019: How AI and Customer-First Strategies Help Sales and Marketing Teams Stay Ahead of the Curve

Posted by Omer Hancer on Wed, May 22, 2019

Today, successful pharma outreach requires a customer-first mindset. This includes personalizing both content and channels, sending content at the right time and in the right channel to match customers’ levels of interest, adapting to physician reactions and humanizing AI sales and marketing suggestions for the rep so they understand why a suggested next best action is made. According to ZS research, personalization has resulted in a 20% increase in open rates for both marketing and rep-triggered emails and up to a 30% uplift in impactable sales.


>
Read More

Intelligent Process Automation: Starting Is Easy, Scaling Is a Different Ball Game

Posted by Vishal Kabra on Thu, May 09, 2019

Satish Jha co-wrote this blog post with Vishal Kabra 

Today, there is no denying that when it comes to increasing efficiency, reducing cost and offering a better customer experience, intelligent process automation (IPA) is a go-to strategy for businesses, and pharma is no exception. IPA promises that it can free up people to do more value-added work and play more strategic roles within their organizations. At a fundamental level, IPA is an emerging set of new technologies that include robotic process automation (RPA), conversational AI and machine learning to mimic activities carried out by humans. With the evolution in IPA technologies and the broad applicability of such automation, IPA continues to be a buzzword in every industry. Given the many benefits and possibilities, it’s understandable why organizations are jumping onto the IPA bandwagon.

However, most organizations aren’t succeeding at scaling intelligent process automation.


>
Read More

Has AI Reached Peak Hype?

Posted by Arun Shastri on Wed, May 08, 2019

Pratap Khedkar co-wrote this blog post with Arun Shastri.

At The Wall Street Journal Health Forum, held in Washington D.C. on April 30, Novartis Chief Executive Vas Narasimhan called artificial intelligence “another tool in the toolbox.” This viewpoint diverges from recent notions that AI is a critical capability that’s going to change the way that pharma companies do business. In fact, industry experts have hoped that the dwindling return on investments for R&D (the current 3% ROI is predicted to hit 0% by 2020) could be reversed by employing AI-based technologies in drug discovery. There are more than 100 AI startups in this field that have received generous investments from venture capital. Yet, IBM has discontinued sales of its Watson AI system for drug discovery.


>
Read More